http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104147002-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 |
| filingDate | 2014-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104147002-B |
| titleOfInvention | Indapamide bisoprolol transdermal skin patches and preparation method thereof |
| abstract | The invention belongs to pharmaceutical technology field, relate to indapamide bisoprolol transdermal skin patches and preparation method thereof.Described indapamide bisoprolol transdermal skin patches is made up of backing layer, medicine carrying pressure-sensitive adhesive layer and adherent layer；Medicine carrying pressure-sensitive adhesive layer includes that indapamide, bisoprolol free alkali or its organic acid ion are to complex, pressure sensitive adhesive, transdermal absorption accelerator.Wherein indapamide, bisoprolol free alkali or its organic acid ion dose total to complex accounts for the 0.5wt% ~ 5.5wt% of medicine carrying pressure-sensitive adhesive layer gross weight, wherein indopamide, bisoprolol free alkali or its organic acid ion are 0.5:1 ~ 2:1 to the molar ratio of complex, the present invention is capable of in transdermal skin patches passing through indapamide and bisoprolol percutaneous the two-ways regulation of ability, it is achieved that two medicines pass through from the synchronized of transdermal skin patches. |
| priorityDate | 2014-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.